Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with moderately to severely active Crohn's disease.
- People for whom a doctor has prescribed upadacitinib for Crohn's disease, in line with the currently approved prescribing guidelines in Japan.
- People who are within 14 days of starting their upadacitinib induction treatment for Crohn's disease at the participating medical institution.
Who may not be able to join:
- People who are currently taking part in another clinical research study that involves a treatment or intervention.
- People for whom upadacitinib is medically unsuitable or not recommended (confirm with trial site).
- People who have previously been treated with upadacitinib for Crohn's disease and are continuing that treatment at the time of joining this study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: +81-3-4577-1111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of Participants with Drug Related Serious Infections
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.